Responses
Clinical/translational cancer immunotherapy
Original research
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.